肺癌

有意团购印度易瑞沙 印度特罗凯 印度力比泰 巴西多吉美 印度多吉美 请加入我们的群
官方QQ群1：26438631  5100806  或QQ 3 5 7 6 8 7 5 注明 www.feiai88.com！

医药开发商辉瑞公司星期一宣布，其治疗肺癌患者的药品Sutent在晚期的实验中失败。
公司称，Sutent(又名sunitinib)没有达到提高之前接受过肺癌治疗患者总体存活率的目标。这项研究中，将服用Sutent和Tarceva(又名erlotinib (特罗凯|埃罗替尼))的病人和仅仅服用Tarceva(特罗凯)的病人作对比。
辉瑞称，Sutent和Tarceva(特罗凯)的搭配使用达到了次要的目标，即提高了病人的无进展生存率。公司将继续分析研究数据。

==== 汉译英 ====
Pfizer pharmaceutical developers on Monday announced that its lung cancer drug Sutent in patients with advanced experiment in failure.
The company said, Sutent (also known as sunitinib) received did not meet before to improve overall survival in patients with lung cancer treatment target. The study, taking Sutent and Tarceva (also known as erlotinib (Tarceva | erlotinib)) patients and only taking Tarceva (Tarceva) in patients for comparison.
Pfizer said, Sutent and Tarceva (Tarceva) is used with a secondary objective to achieve, namely to improve the progression-free survival rate of patients. Will continue to analyze the research data.